Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : GUMM - Eliminate the Common Cold -- Ignore unavailable to you. Want to Upgrade?

To: DanZ who wrote (812)	8/28/1999 4:59:00 PM
From: Mike M	Respond to of 5582

I have to give you and Howard credit. Your patience to respond to mad2 is admirable. Mad2 asks reasonable questions but are tiresome at this point. Of course, this investment has risk. Of course, the price reflects some expectation for Zicam and other gum products. It isn't a big secret that Zicam is expected to accelerate distribution this year and the possibility exists that the NEJM may validate the efficacy of the product. Nor is it a secret that investors expect significant oral and nicotine agreements to materialize this year. Finally, if these things do not materialize then we will see disappointment and selling pressure. No this isn't PFE or MRK. Da! This investment is more speculative than PFE or MRK and should be made with that understanding. The risk is great but then so is the potential reward. Mad2 acts like he does not understand risk and yet we know he is prone to short. Once the risk is no longer an issue(say Zicam becomes a huge hit) then the potential reward diminishes accordingly. So you take your chances. Some believe that this glass is half full. Like me! Mike